Riva Fineman
- Molecular Medicine top 5%
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 17
- Infectious Diseases top 10%
- Endocrinology top 10%
- Enterobacteriaceae and Cronobacter Research 2
-
- Lymphoma Diagnosis and Treatment 10
-
- Chronic Myeloid Leukemia Treatments 5
- Acute Myeloid Leukemia Research 3
-
- CAR-T cell therapy research 4
-
- Immunodeficiency and Autoimmune Disorders 4
-
- Antibiotics Pharmacokinetics and Efficacy 3
- Co-authors
- Tsila ZuckermanNoam BenyaminiJacob M. RoweI. OrenH. SprecherTamar TadmorOsnat BaireyLev Shvidel
- Journals
- Blood (7 papers)The American Journal of Cardiology (1 paper)British Journal of Haematology (1 paper)
- Partner nations
- IsraelUnited States
In The Last Decade
Riva Fineman
30 papers receiving 494 citations
Peers
Comparison fields: 5 of 58
- Molecular Medicine 124
- Genetics 171
- Applied Microbiology and Biotechnology 25
- Infectious Diseases 151
- Endocrinology 40
Countries citing papers authored by Riva Fineman
This map shows the geographic impact of Riva Fineman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Riva Fineman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Riva Fineman more than expected).
Fields of papers citing papers by Riva Fineman
This network shows the impact of papers produced by Riva Fineman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Riva Fineman. The network helps show where Riva Fineman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Riva Fineman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2021 | 44 | |
| 3 | 2021 | 73 | |
| 4 | 2019 | 10 | |
| 5 | 2019 | 2 | |
| 6 | 2018 | 5 | |
| 7 | 2018 | 8 | |
| 8 | 2017 | 3 | |
| 9 | 2015 | 23 | |
| 10 | 2014 | 2 | |
| 11 | Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group. | 2014 | 32 |
| 12 | 2014 | 27 | |
| 13 | 2013 | 69 | |
| 14 | 2012 | 5 | |
| 15 | 2012 | 2 | |
| 16 | 2010 | 63 | |
| 17 | 2006 | 46 | |
| 18 | 2006 | 2 | |
| 19 | Long-term survivors of childhood malignancies--aeromedical dilemmas and implications. | 2006 | 2 |
| 20 | 1996 | 3 |
About Riva Fineman
Riva Fineman is a scholar working on Genetics, Hematology and Transplantation, having authored 30 papers that have together received 501 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (10 papers), Chronic Myeloid Leukemia Treatments (5 papers), CAR-T cell therapy research (4 papers), Immunodeficiency and Autoimmune Disorders (4 papers), Acute Myeloid Leukemia Research (3 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Enterobacteriaceae and Cronobacter Research (2 papers). The work is most often cited by research in Molecular Medicine (124 citations), Genetics (171 citations) and Applied Microbiology and Biotechnology (25 citations). Riva Fineman has collaborated with scholars based in Israel and United States. Frequent co-authors include Tsila Zuckerman, Noam Benyamini, Jacob M. Rowe, I. Oren, H. Sprecher, Tamar Tadmor, Osnat Bairey, Lev Shvidel, Aaron Polliack and Neta Goldschmidt. Their work appears in journals such as Blood, The American Journal of Cardiology and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.